摘要
目的观察伏立康唑治疗缺血性脑卒中患者耐氟康唑白色念珠菌肺部感染的临床疗效与安全性。方法13例临床真菌培养和涂片检查确诊为肺部白色念珠菌感染,已接受静脉滴注氟康唑治疗至少1周但无效,病原学检查证实为耐氟康唑白色念珠菌感染的病情相对稳定的缺血性脑卒中重症患者,接受国产注射用伏立康唑治疗。观察患者症状和体征变化,评价感染治愈率及治疗安全性。结果共有12例患者纳入疗效分析,痊愈率为83.33%,总有效率为100%。仅1例患者治疗中出现丙氨酸氨基转移酶及乳酸脱氢酶水平稍增高,停药后恢复正常,未见其他不良反应。结论伏立康唑用于治疗缺血性脑卒中患者耐氟康唑白色念珠菌肺部感染安全且有效。
Objective To observe the efficacy and safety of voriconazole in the treatment of fluconazole resistant Candida albicans pulmonary infection in patients with cerebral infarction. Methods Thirteen patients with cerebral infarction complicating Candida albicans pulmonary infection which had no response to fluconazole at least one week were enrolled and were administered voriconazole. Results Twelve patients were enrolled into statistical analysis. The fully recovery rate and total effective rate were 83.33 % and 100% respectively. Only one patient was found of increased alanine aminotransferase and lactate dehydrogenase. Conclusion Voriconazole may be used effectively and safely for the treatment of fluconazole resistant Candida albicans pulmonary infection in patients with cerebral infarction.
出处
《世界临床药物》
CAS
2009年第7期414-416,共3页
World Clinical Drug
关键词
缺血性脑卒中
伏立康唑
氟康唑
耐药
白色念珠菌
cerebral infarction
voriconazole
fluconazole
resistant
Candida albicans
